Relationship between PSA kinetics and [ 18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 2, 2012, Pages 271-282

  Graute, Vera ^a   Jansen, Nathalie ^a   Übleis, Christopher ^a   Seitz, Michael ^a   Hartenbach, Markus ^b   Scherr, Michael Karl ^c   Thieme, Sven ^c   Cumming, Paul ^a   Klanke, Katharina ^a   Tiling, Reinhold ^a   Bartenstein, Peter ^a   Hacker, Marcus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Bundeswehrkrankenhaus Ulm ^*  (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

18F fluorocholine PET CT; Detection rate; Prostate specific antigen; Recurrence; Total prostatectomy

Indexed keywords

FLUOROCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RECURRENCE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; CHOLINE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KINETICS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TIME FACTORS;

EID: 84859647253     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1970-2     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. doi:10.3322/CA.2007.0010. (Pubitemid 351521864)
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr/. Accessed 26 Oct 2011.
3. Freedland SJ, Presti Jr JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-41. (Pubitemid 36384965)
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-23. doi:10.1097/01.ju.0000045749.90353.c7. (Pubitemid 36132976)
5. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380-5. doi:10.1016/j.ijrobp.2003.10.059. (Pubitemid 38622589)
6. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2010;52:81-9.
7. National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Prostate. http://seer.cancer.gov/statfacts/html/prost. html. Accessed 26 Oct 2011.
8. Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9-17. (Pubitemid 350234137)
9. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. doi:10.1016/j.urolonc.2010.08.008.
10. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/ CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-400. doi:10.2967/jnumed.108.061507.
11. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55-63. doi:10.1007/s00259- 010-1604-0.
12. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274-8. doi:10.1097/01.ju.0000097124.21878.6b. (Pubitemid 37413974)
13. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer. 2006;106:1047-53. doi:10.1002/cncr.21696.
14. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32-8. discussion 8-9.
15. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623-8. doi:10.1148/radiol.2352040494. (Pubitemid 40571106)
16. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387-98. doi:10.1007/s00259-006-0150-2. (Pubitemid 44885404)
17. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23. doi:10.1007/s00259-007-0581-4. (Pubitemid 350234152)
18. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-93. doi:10.1111/j.1464- 410X.2007.07083.x. (Pubitemid 47360183)
19. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA, et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:160-4. doi:10.1016/j.ijrobp.2009.04.090.
20. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895-904. doi:10.1007/s11547-008-0263-8.
21. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301-9. doi:10.1007/s00259-009-1253-3.
22. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C] choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106-16. doi:10.1007/s00259- 010-1403-7.
23. Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635-50. doi:10.1177/1073858409338217.
24. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51-60. doi:10.1016/j.eururo. 2010.09.004.
25. Richter JA, Rodriguez M, Rioja J, Penuelas I, Marti-Climent J, Garrastachu P, et al. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol. 2010;12:210-7. doi:10.1007/s11307-009-0243-y.
26. Kataja VV, Bergh J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol. 2005;16 Suppl 1:i34-6.
27. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805-14.
28. Muller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging. 2009;36:1434-42. doi:10.1007/s00259-009-1117-x.
29. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-73. doi:10.1007/s00259-008- 0716-2.